Italia markets closed

Dow Jones
39.837,61
+30,84(+0,08%)
Nasdaq
16.792,46
-2,41(-0,01%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0859
-0,0002(-0,02%)
Bitcoin EUR
64.337,38
+1.533,92(+2,44%)
CMC Crypto 200
1.525,82
+37,28(+2,50%)

NVCR Dec 2025 10.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

8,00

0,00

(0,00%)

In data: 11:40AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in